Off-Target Screening of Biotheraputics | Cell Microarray Applications : Retrogenix

Off-Target Screening of Biotherapeutics

Biotherapeutics cross-reactivity

Toxicity due to off-target binding is a leading cause of failure in drug development. Retrogenix’s Cell Microarray screening can provide an understanding of the off-target binding potential of novel biologic drug leads during discovery and early development. Building a picture of the ‘toxic liability’ of a candidate drug helps reduce risk through more informed safety assessment and can save considerable time and resources by allowing bad drugs to fail earlier. Retrogenix’s off target screening data has been used in regulatory submissions for clinical studies.

Retrogenix off target profiling:

Identifies specific plasma membrane off-targets
Provides supporting information for IND regulatory submissions
Is highly specific with very low numbers of false positives/negatives
Complements tissue cross reactivity (TCR) and immunohistochemistry studies
Can predict/explain reduced bioavailability due to off-target binding
Can inform pre-clinical tox model selection, reducing animal testing
Helps prioritise drug leads or avoid off-target activities in next-generation of molecules

Low false positive rate

Our highly specific screen typically reports one or two confirmed interactions rather than 100s of erroneous results that can often be seen with protein microarrays. This saves months of validation work and avoids unnecessary investigations that could stall progress with regulatory submissions.

Please contact us to discuss an off-target project.

Screen for off-targets of:

Antibodies & bispecifics
ADCs
ScFvs, Fabs or antibody derivatives
whole CAR T cells
Peptides
Protein ligands
Labelled small molecules

“Specificity screening of antibodies and related molecules using human cell microarray technology.”

Download our poster, presented at PEGS 2017, which describes how the cell microarray approach is being applied to identify specific and relevant off-targets with a very low rate of false positive results.

Download poster

FAQ: “What is the sensitivity of the Cell Microarray technology?”

Ligand-receptor interactions of around 10 micromolar can be detected in the absence of any amplification strategy. This is more than adequate for most studies, however, amplification strategies can be employed when needed in order to detect lower affinity interactions.

See more FAQs

Talk to us about a project

Peptinnovate Ltd - Unlocking Nature's Potential

Thank you again for your professionalism, for a fine analysis, and for our enjoyable scientific exchanges.

Professor Gunnar Lindahl, Lund University, Sweden